Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Currently, heart disease is being considered as the leading cause of death among men and women worldwide. And about 610,000 people die of heart disease in the USA annually. Heart disease includes coronary heart disease, congestive heart failure, heart attack and congenital heart disease with coronary heart disease being the most common type; about 375,000 Americans die of heart disease each year.
Many signaling pathways are associated with cardiac function, some of which are beneficial and others injurious. The cardiovascular disease (CVD) state is largely affected by the balance between these signaling pathways, and selective protein kinase inhibitors are being widely studied as potential new selective therapeutic agents which can substitute traditional receptor blockers for treating CVD. For instance, myocardial ischemia is claimed to be caused by the disruption of tightly structured and consistent signaling pathways. Recent studies have uncovered three emerging mechanisms of cell death in the ischemic heart: first of all, the mitochondrial permeability transition and its effector, the mitochondrial permeability transition pore, which is regulated by the PI3K-AKT-GSK3 kinase axis; second, the programmed myocardial cell death, which is regulated by the interacting protein 1 and 3 kinases. Finally, there is the Ca2+ overload-induced mitochondrial dysfunction, which is regulated by mitochondrial calcium uniporter and Ca2+ calmodulin (CaM)-CaMK-II. Inhibition of each of these kinase pathways has been proposed as a way to limit myocyte death from ischemia/reperfusion injury.
Aberrant kinase activity in CVD is due to enhanced stimulation through the activated neurohormonal system. Various kinases are involved in modulating cardiac function through phosphorylation. And many kinase inhibitors have been used as research tools to test the putative anticardiac disease activity. Creative Biogene can offer the largest commercial portfolio of kinase assay solutions for cardiovascular research areas. Select targets are shown - view more kinase targets.
Copyright © Creative Biogene. All rights reserved.